Recent advances in natriuretic peptides in congestive heart failure

Guido Boerrigter, John C Jr. Burnett

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

Original languageEnglish (US)
Pages (from-to)643-652
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume13
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Heart Failure
Neprilysin
Atrial Natriuretic Factor
Enzymes

Keywords

  • Cyclic guanosine monophosphate
  • Heart failure
  • Natriuretic peptides
  • Nesiritide
  • Neurohumoral activation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Recent advances in natriuretic peptides in congestive heart failure. / Boerrigter, Guido; Burnett, John C Jr.

In: Expert Opinion on Investigational Drugs, Vol. 13, No. 6, 06.2004, p. 643-652.

Research output: Contribution to journalArticle

@article{0e34769551e94afe86cce57d85cbabf8,
title = "Recent advances in natriuretic peptides in congestive heart failure",
abstract = "Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004",
keywords = "Cyclic guanosine monophosphate, Heart failure, Natriuretic peptides, Nesiritide, Neurohumoral activation",
author = "Guido Boerrigter and Burnett, {John C Jr.}",
year = "2004",
month = "6",
doi = "10.1517/13543784.13.6.643",
language = "English (US)",
volume = "13",
pages = "643--652",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Recent advances in natriuretic peptides in congestive heart failure

AU - Boerrigter, Guido

AU - Burnett, John C Jr.

PY - 2004/6

Y1 - 2004/6

N2 - Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

AB - Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

KW - Cyclic guanosine monophosphate

KW - Heart failure

KW - Natriuretic peptides

KW - Nesiritide

KW - Neurohumoral activation

UR - http://www.scopus.com/inward/record.url?scp=3042847645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042847645&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.6.643

DO - 10.1517/13543784.13.6.643

M3 - Article

C2 - 15174950

AN - SCOPUS:3042847645

VL - 13

SP - 643

EP - 652

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -